Logo do repositório
 
Publicação

Application of optical coherence tomography angiography for microvascular changes in patients treated with hydroxychloroquine

2023-08Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorFerreira, André
dc.contributor.authorAnjos, Rita
dc.contributor.authorJosé-Vieira, Rafael
dc.contributor.authorAfonso, Miguel
dc.contributor.authorAbreu, Ana Carolina
dc.contributor.authorMonteiro, Sílvia
dc.contributor.authorMacedo, Mafalda
dc.contributor.authorAndrade, José P.
dc.contributor.authorFurtado, Maria João
dc.contributor.authorLume, Miguel
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblSpringer Verlag
dc.date.accessioned2023-03-21T22:27:36Z
dc.date.available2023-03-21T22:27:36Z
dc.date.issued2023-08
dc.description.abstractBackground: Retinal toxicity with long-term hydroxychloroquine (HCQ) treatment is a major concern. This systematic review aims to assess the application of optical coherence tomography angiography (OCTA) to detect microvascular alterations in patients under HCQ. Methods: PubMed, Scopus, Web of Science, and Cochrane Library databases were systematically searched until January 14, 2023. Studies using OCTA as a primary diagnostic method to evaluate the macular microvasculature of HCQ users were included. Primary outcomes were macular vessel density (VD) and foveal avascular zone (FAZ) at the superficial (SCP) and deep (DCP) capillary plexus. Meta-analysis was performed using a random-effects model. Results: Of 211 screened abstracts, 13 were found eligible, enrolling 989 eyes from 778 patients. High-risk patients due to longer duration of treatment presented lower VD in the retinal microvasculature than those with low-risk in SCP (P = 0.02 in fovea; P = 0.004 in parafovea) and in DCP (P = 0.007 in fovea; P = 0.01 in parafovea). When compared with healthy controls, HCQ users had lower VD in both plexus—no quantitative synthesis was presented. Conclusions: Microvascular changes were found in autoimmune patients under HCQ treatment without any documented retinopathy. However, the evidence produced so far does not allow to draw conclusion concerning the effect of drug as studies were not controlled for disease duration. [Figure not available: see fulltext.].en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent2073351
dc.identifier.doi10.1007/s00417-023-06023-2
dc.identifier.issn0721-832X
dc.identifier.otherPURE: 56484339
dc.identifier.otherPURE UUID: 0b69823b-82e3-49c4-9a64-829d560bb7b4
dc.identifier.otherScopus: 85149907246
dc.identifier.otherPubMed: 36884062
dc.identifier.urihttp://hdl.handle.net/10362/151015
dc.identifier.urlhttps://www.scopus.com/pages/publications/85149907246
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAutoimmune diseases
dc.subjectHydroxychloroquine
dc.subjectMacula lutea
dc.subjectMicrovasculature
dc.subjectOptical coherence tomography angiography
dc.subjectOphthalmology
dc.subjectSensory Systems
dc.subjectCellular and Molecular Neuroscience
dc.titleApplication of optical coherence tomography angiography for microvascular changes in patients treated with hydroxychloroquineen
dc.title.subtitlea systematic review and meta-analysisen
dc.typejournal article
degois.publication.firstPage2221
degois.publication.lastPage2233
degois.publication.titleGraefe's Archive for Clinical and Experimental Ophthalmology
degois.publication.volume261
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
s00417_023_06023_2.pdf
Tamanho:
1.98 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica